Gena Lee Meyers

Director, Business Development at Curocell

Presenter

Curocell is a commercial-stage cell therapy company spanning from development to commercial manufacturing. Our mission is to transform cancer treatment by developing innovative, robust, and scalable cell therapy solutions that improve patient outcomes worldwide. We integrate scientific excellence with strategic business development to accelerate global access to life-saving immunotherapies. By leveraging our deep expertise in CAR-T CMC, we aim to develop collaborations with cell therapy companies that share the same mission. Our strong foundation in research and clinical studies enables us to bridge the gap between research, process optimization, and commercialization. We focus on enhancing manufacturing efficiency, regulatory compliance, and scalability to bring safe and effective treatments to market faster. At the heart of our innovation is our proprietary OVIS™ (Overcome Immune Suppression) technology, which significantly inhibits the expression of PD-1 and TIGIT, two immune checkpoint receptors known to impede CAR-T cell function. This groundbreaking approach has shown impressive efficacy in clinical trials, with our lead asset Anbal-cel achieving a 67.1% complete response rate in Phase 2 trials for relapsed or refractory DLBCL. Our commitment to advancing cell therapy extends beyond our own pipeline. We have established Korea's largest-scale GMP facility dedicated to CAR-T production, positioning us as a leader in the field. As we continue to expand our capabilities and explore new indications, including ALL and SLE, we remain dedicated to our goal of revolutionizing the treatment landscape for hematological malignancies and beyond.